Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Wednesday, March 12th. Analysts expect Indaptus Therapeutics to post earnings of ($0.41) per share for the quarter.
Indaptus Therapeutics Trading Down 0.6 %
NASDAQ INDP opened at $0.82 on Tuesday. The company has a 50-day moving average price of $0.86 and a two-hundred day moving average price of $1.10. Indaptus Therapeutics has a 52 week low of $0.70 and a 52 week high of $3.10. The stock has a market cap of $11.58 million, a price-to-earnings ratio of -0.48 and a beta of 1.60.
Analyst Upgrades and Downgrades
Separately, Maxim Group decreased their price objective on Indaptus Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a report on Wednesday, November 13th.
Indaptus Therapeutics Company Profile
Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
See Also
- Five stocks we like better than Indaptus Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- How to Protect Your Portfolio When Inflation Is Rising
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- How to Buy Cheap Stocks Step by Step
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
